#United States #IceCure Medical #ProSense #Portland #Legacy Health

IceCure Medical Expands ProSense® Study in Portland, OR

In a significant advancement for breast cancer treatment options, IceCure Medical Ltd. (NASDAQ: ICCM) has announced the inclusion of Legacy Health in Portland, Oregon, as a new U.S. clinical site for its ongoing ProSense® ChoICE Study. The study aims to evaluate the effectiveness and safety of ProSense® cryoablation, a minimally invasive technology that destroys tumors by freezing, as a preferred alternative to surgical tumor removal for low-risk breast cancer patients.

Background on the ChoICE Study

The ChoICE Study is a post-marketing research initiative approved by the U.S. Food and Drug Administration (FDA). It seeks to provide deeper insights into the performance of ProSense® in real-world clinical settings for breast cancer treatments. The study plans to enroll approximately 400 patients across 30 clinical sites throughout the United States.

The involvement of Legacy Health, which boasts a solid reputation in oncology, brings a wealth of clinical expertise to the study. The co-primary investigator for this site, Dr. Nathalie Johnson, serves as the Senior Medical Director at the Legacy Cancer Institute. Dr. Johnson's leadership, alongside other co-investigators, including Marco Aru and Jennifer Garreau, will guide the site’s participation in the ChoICE Study.

Why ProSense®?

ProSense® has proven to be a groundbreaking solution for patients with biologically low-risk tumors, particularly for women aged 70 and older who may be ineligible for surgical options. It is the first and only medical device cleared by the FDA for this specific demographic. The therapy’s approach allows for localized treatment, thereby preserving surrounding healthy tissue and facilitating a shorter recovery time.

By employing cryoablation, a process that uses extreme cold to target and destroy cancerous cells, ProSense® offers a viable alternative for patients seeking to avoid the invasiveness of traditional surgery. This characteristic significantly enhances the quality of life for those battling breast cancer.

Expert Comments

Eyal Shamir, the CEO of IceCure Medical, expressed enthusiasm about the involvement of Dr. Johnson and Legacy Health in the study. “As a nationally recognized breast cancer expert, we are excited to welcome Dr. Nathalie Johnson and the Legacy Good Samaritan site to the ChoICE Study,” he stated. “Her experience and knowledge represent an important milestone for the study as we aim to expand patient access and enhance evidence supporting cryoablation for low-risk breast cancer.”

The Future of Cryoablation for Breast Cancer

The ChoICE Study's commitment to evaluating ProSense® is more than just a trial; it signifies a broader shift toward more innovative and patient-centered approaches in cancer treatment. With over 14,000 employees and a network of clinics, Legacy Health is well-equipped to support the enrollment process and comprehensive patient care throughout the study.

This initiative potentially marks a new chapter in breast cancer management, paving the way for enhanced treatment alternatives that prioritize patient safety and quality of life. As enrollment progresses, the study aims to gather substantial clinical data that may validate the role of cryoablation as a standard care option for patients with low-risk breast cancers across various medical landscapes.

For additional insights and updates surrounding the ongoing study, IceCure Medical and Legacy Health will continue to collaborate closely, focusing on their mission to advance cancer treatment protocols.

About the Companies

IceCure Medical is dedicated to developing and marketing advanced cryoablation therapy systems, particularly targeting tumors in the breast, kidney, bone, and lung. Legacy Health, known for its extensive care network across Oregon and Washington, prioritizes patient-centered healthcare and engages in a broad array of services.

To learn more about IceCure Medical and its innovative approaches to cancer treatment, please visit IceCure's website. For more details on Legacy Health and its offerings, visit Legacy Health's website.